Do XXXX increase the risk of @entity0 ?

@entity1 @entity0 @entity74 @entity62 @entity259 @entity1374
The objective of this study was to determine whether @entity1374 or treatment of @entity74 affects the risk of @entity0 . Subjects aged 35-64 years were @entity1 in the National Institute of @entity1 Health and @entity1 Development @entity1 's Contraceptive and Reproductive Experiences Study, a population-based, case-control study of @entity0 that was carried out at five sites in the United States. In- @entity1 interviews were completed for 4575 @entity1 (cases) with @entity0 (2953 white and 1622 black) and 4682 control @entity1 (3021 white and 1661 black). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multiple logistic regression methods. Models included adjustment for age (5-year age groups), race ( @entity62 ), and site. A history of any @entity1374 (OR = 1.1, 95% CI = 0.9-1.2) was not associated with @entity0 risk. Only @entity1 with a history of @entity259 had an increased risk, but this was restricted to parous @entity1 (parous OR = 3.4, 95% CI = 1.5-8.1; nulliparous OR = 0.5, 95% CI = 0.04-5.1). @entity0 risk was not associated with treatment for @entity1374 . There was no statistical interaction between @entity1374 , thyroid treatments, and race, menopausal status, or parity. We found no association between @entity1374 or their associated treatments and the risk of @entity0 .
